Ngnz.
Iil should have consulted the FDA re design study re P2b prior to the start.
Since then Iil have been in touch with the FDA re design P3.
Results due in August / Sept.but now to be released in June..
Which tells me that the P2 b study should have had more patients and more clinical data..
Just my opinion....hope I'm wrong.
Ann: Trading Halt, page-11
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
